uniQure (QURE) Announces Closing of CSL Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
uniQure BV (QURE) Risk/Reward 'Heavily Skewed To The Upside' - Raymond James
May 6, 2021 9:44 AM EDTRaymond James analyst Danielle Brill reiterated a Strong Buy rating and $75.00 price target on uniQure BV (NASDAQ: QURE) after announcing the licensing agreement with CSL Behring for its HemB gene therapy (etranacogene dezaparvovec (EtranaDez)) has closed.
"In our view, the hemophilia-B gene... More
